Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-18T05:28:18.889Z Has data issue: false hasContentIssue false
  • English
  • Français

Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

Published online by Cambridge University Press:  02 January 2018

Charles M. Beasley Jr ,
Mary Anne Dellva ,
Roy N. Tamura ,
Hal Morgenstern ,
William M. Glazer ,
Kevin Ferguson  and
Gary D. Tollefson
Charles M. Beasley Jr*
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
Mary Anne Dellva
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
Roy N. Tamura
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN
Hal Morgenstern
Affiliation:
School of Public Health, University of California at Los Angeles
William M. Glazer
Affiliation:
Harvard Medical School, Boston, MA
Kevin Ferguson
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
Gary D. Tollefson
Affiliation:
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA
*
Charles M. Beasley, Jr, MD, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0538, Indianapolis, IN 46285, USA. Tel: (317) 276-4994; Fax: (317)277-7839
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Tardive dyskinesia is important in the side-effect profile of antipsychotic medication.

Aims

The development of tardive dyskinesia was evaluated in patients treated with double-blind, randomly assigned olanzapine or haloperidol for up to 2.6 years.

Methods

Tardive dyskinesia was assessed by the Abnormal Involuntary Movement Scale (AIMS) and Research Diagnostic Criteria for Tardive Dyskinesia (RD-TD); it was defined as meeting RD-TD criteria at two consecutive assessments. The risk of tardive dyskinesia, the relative risk, incidence rate, and incidence rate ratio were estimated.

Results

The relative risk of tardive dyskinesia for the overall follow-up period for haloperidol (n=522) v. olanzapine (n=1192) was 2.66 (95% CI=1.50–4.70). Based on data following the initial six weeks of observation (during which patients underwent medication change and AIMS assessments as frequently as every three days), the one-year risk was 0.52% with olanzapine (n=513) and 7.45% with haloperidol (n=114). The relative risk throughout this follow-up period was 11.37 (95% Cl=2.21–58.60).

Conclusion

Our results indicated a significantly lower risk of tardive dyskinesia with olanzapine than with haloperidol.

Type
Papers
Information
The British Journal of Psychiatry , Volume 174 , Issue 1 , January 1999 , pp. 23 - 30
Copyright
Copyright © 1999 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

Declaration of interest

Sponsored by Eli Lilly and Company.

References

American Psychiatric Association (1997) Diagnostic and Statistical Manual of Mental Disorders (3rd edn, revised). Washington, DC: APA.Google Scholar
Barnes, T. R. E. (1989) A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676.CrossRefGoogle ScholarPubMed
Beastey, C. M. Jr., Tollefson, G., Tran, P., et al (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology, 14, 111–123.CrossRefGoogle Scholar
Beastey, C. M., Hamilton, S., Crawford, A. M., et al (1997) Olanzapine versus haloperidoi: Acute-phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology, 7, 125–137.CrossRefGoogle Scholar
Casey, D. E. (1995) Tardive dyskinesia: pathophysiology. In Psychopharrnacology: The fourth Generation of Progress (eds Bloom, F. E. and Kupfer, D. J.), p. 1497. New York: Raven Press.Google Scholar
Chakos, M. H., Alvir, J. M., Woerner, M. G., et al (1996) Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Archives of General Psychiatry, 53, 313–319.Google Scholar
Chouinard, G., Annable, L., Mercier, P., et al (1986) A five year follow-up study of tardive dyskinesia. Psychopharmacology Bulletin, 22, 259–263.Google ScholarPubMed
Efron, B. & Tibshirani, R. J. (1993) An Introduction to the Bootstrap, pp. 184–188. New York: Chapman and Hall.Google Scholar
Fulton, B. & Goa, K. L. (1997) Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs, 53, 281–298.Google Scholar
Gardos, G. & Cole, J. O. (1983) Tardive dyskinesia and anticholinergic drugs. American Journal of Psychiatry, 140. 200–202.Google Scholar
Gardos, G., Perenyi, A., Cole, J. O., et al (1988) Seven-year follow-up of tardive dyskinesia in Hungarian outpatients. Neuropsychopharmacology. 1, 169–172.CrossRefGoogle ScholarPubMed
Gibson, A. C. (1981) Incidence of tardive dyskinesia in patients receiving depot neuroleptic injection. Acta Psychiatrica Scandinavika Supplementum, 291, 111–116.CrossRefGoogle ScholarPubMed
Guy, W. (1976) Assessment Manual for Psychopharmacology (revised version). Rockville. MD: US Department of Health. Education and Welfare.Google Scholar
Inada, T., Ohnishl, K., Kamisada, M., et al (1991) A prospective study of tardive dyskinesia in Japan. European Archives of Psychiatry and Clinical Neuroscience, 240, 250–254.Google Scholar
Kane, J. M., Woerner, M., Weinhold, P., et al (1982) A prospective study of tardive dyskinesia development: preliminary results. Journal of Clinical Psychopharmacolgy, 2, 345–349.Google ScholarPubMed
Kane, J. M., Woerner, M., Borenstein, M., et al (1986) Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacolgy Bulletin, 22, 254–258.Google Scholar
Kane, J. M., Woerner, M., Pollack, S., et al (1993) Does clozapine cause tardive dyskinesia? Journal of Clinical Psychiatry, 54, 327–330.Google Scholar
Miller, C. H., Simioni, I., Oberbauer, H., et al (1995) Tardive dyskinesia prevalence rates during a ten-year follow-up. Journal of Nervous and Mental Disease, 183, 404–407.Google Scholar
Morgenstern, H. & Glazer, W. M. (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry, 50, 723–733.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.Google Scholar
Rothman, K. J. (1986) Stratified analysis. In Modem Epidemiology, p. 177. Boston. MA: Little Brown.Google Scholar
Schooler, N. R. & Kane, J. M. (1982) Research diagnoses for tardive dyskinesia (letter). Archives of General Psychiatry, 39, 486–487.Google Scholar
Simpson, G. M. & Angus, J. W. S. (1970) A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 212 (suppl.). S11–S19.Google Scholar
Tolliefson, G. D., Baasley, C. M., Tamura, R. N., et al (1997a) A blinded, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesias with olanzapine or haloperidoi. American Journal of Psychiatry, 154, 1248–1254.Google Scholar
Tolliefson, G. D., Baasley, C. M., Tran, P. V., et al (1997b) Olanzapine versus haloperidoi in the treatment of schizophrenia and schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry, 154, 457–465.Google Scholar
Waddington, J. L., Youssef, H. A., Dolphin, C., et al (1987) Cognitive dysfunction, negative symptoms, and tardive dyskinesia in schizophrenia. Their association in relation to topography of involuntary movements and criterion of their abnormality. Archives of General Psychiatry 44, 907–912.Google Scholar
Waddington, J. L., Youssef, H. A. & Kinsella, A. (1990) Cognitive dysfunction in schizophrenia followed up over 5 years and its longitudinal relationship to the emergence of tardive dyskinesia. Psychological Medicine, 20. 835–842.Google Scholar
Wagstaff, A. J. & Bryson, H. M. (1995) Clozapine: a review of its pharmacological properties and therapeutic use in patients with schizophrenia who are unresponsive to or intolerant of classical antipsychotic agents. CNS Drugs. 4, 371–400.Google Scholar
Yassa, R. & Nair, V. (1984) Incidence of tardive dyskinesia in an outpatient population. Psychosomatics, 25, 479–481.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.